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This study was aimed to investigate whether brain-derived neurotrophic factor (BDNF) can modulate local cerebral inﬂammation
in ischemic stroke. Rats were subjected to ischemia by occluding the right middle cerebral artery (MCAO) for 2 hours. Rats were
randomizedascontrol,BDNF, andantibody groups.The localinﬂammationwasevaluatedon cellular,cytokine, andtranscription
factor levels with immunoﬂuorescence, enzyme-linked immunosorbent assay, real-time qPCR, and electrophoretic mobility shift
assay, respectively. Exogenous BDNF signiﬁcantly improved motor-sensory, sensorimotorfunction, and vestibulomotor function,
while BDNF did not decrease the infarct volume. Exogenous BDNF increased the number of both activated and phagocytotic
microglia in brain. BDNF upregulated interleukin10 and its mRNA expression, while downregulated tumor necrosis factor α and
its mRNA expression. BDNF also increased DNA-binding activity of nuclear factor-kappa B. BDNF antibody, which blocked the
activity of endogenous BDNF, showed the opposite eﬀect of exogenous BDNF. Our data indicated that BDNF may modulate local
inﬂammationin ischemic brain tissues on the cellular, cytokine, and transcription factor levels.
1.Introduction
Stroke is a major cause of death and long-term disability
worldwide [1, 2]. Brain-derivedneurotrophic factor (BDNF)
can decrease infarct volume and improve neurological
outcome either by exogenously supplied or overexpression
in vivousing genetic methods inexperimental stroke. Inhibi-
tion of BDNF exaggerates damage of ischemia. BDNF exerts
neuron protection against ischemic injury through binding
to two membrane receptors, p75 neurotrophin receptor and
tyrosine kinase receptor B (trkB) [3]. 7,8-dihydroxyﬂavone
asabioactivehigh-aﬃnityTrkBagonistalsoprotectsneurons
from apoptosis and decreases infarct volumes in animal
model of stroke [4].
Inﬂammation plays an essential role in the pathogenesis
of ischemic stroke [5, 6]. Rapid activation ofresident inﬂam-
matory cells (mostly microglia), productions of inﬂamma-
tory cytokines such as interlerukin10 (IL-10) and tumor
necrosis factor α (TNF-α) and translocation of intercellular
transcription factors such as nuclear factor-kappa B (NF-κB)
are characters of local inﬂammatory responses to ischemia
in brain [7–11]. Diﬀerent responses may have diﬀerent
functions in the pathogenesis of stroke. Activated microglia
could excrete neurotrophic eﬀects such as BDNF to alleviate
ischemic injury and exhibit phagocytic activity disposing of
degenerating elements [7, 11]. There are several cytokines
involved in inﬂammatory process. TNF-α,a sa ni m p o r t a n t
proinﬂammatory cytokine, appears to exacerbate cerebral
injury of ischemia [8] while IL-10, an anti-inﬂammatory
cytokine, ameliorates ischemic insult of brain [9]. Activation
of NF-κB, an important transcription factor, could mediate
translation of many downstream genes and promote survival
of neurons [10].
BDNF promotes cell proliferation, increases phagocytic
activity and inhibits apoptosis of microglia in brain [12].
BDNF downregulates the expression of TNF-α and upregu-
lates the expression of IL10 in the model of multiple sclerosis
[13]. NF-κB activated by BDNF protects cells from damages,
such as the serum starvation and glutamate toxicity [14].
However, whether BDNF modulates inﬂammatory processes
in ischemic stroke is unclear. In present study, we evaluated
theeﬀectofBDNFonlocalcerebralinﬂammatory processon2 Mediators of Inﬂammation
Table 1: Procedure of the experiment.
Group n −3h −2h 0h 6h 24h
Control 18 PBS MCAO & PBS Reperfusion Sacriﬁce Sacriﬁce
BDNF 18 PBS MCAO & BDNF Reperfusion Sacriﬁce Sacriﬁce
Antibody 18 Ab MCAO & PBS Reperfusion Sacriﬁce Sacriﬁce
PBS, phosphate buﬀered saline; MCAO, middle carotid artery occlusion; BDNF, brain-derived neurotrophic factor; Ab, BDNF antibody. “−”, before
reperfusion.
Table 2: Physiological parameters per- and during ischemia.
Group pH PaCO2 (mmHg) PaO2 (mmHg) MABP (mmHg) T(◦C)
Control pre 7.45 ±0.02 36.5 ±1.9 132.0 ±13.07 4 .8 ± 13.13 7 .1 ±0.33
during 7.43 ±0.02 39.5 ±3.4 123.3 ±20.18 1 .2 ± 10.93 6 .9 ±0.30
BDNF pre 7.45 ±0.01 37.8 ±3.3 119.2 ±13.17 7 .3 ± 11.93 7 .0 ±0.34
during 7.42 ±0.01 40.5 ±4.4 140.3 ±20.18 5 .2 ± 11.63 7 .2 ±0.50
Antibody pre 7.45 ±0.02 36.4 ±3.7 139.8 ±16.77 4 .0 ± 14.73 6 .9 ±0.34
during 7.45 ±0.01 40.2 ±3.9 124.8 ±11.57 8 .6 ± 15.23 7 .1 ±0.40
Pre, preischemia; during, during ischemia (1 hour after onset of MCAO); pH, arterial pH; PaCO2, arterial carbon dioxide partial pressure; PaO2,a r t e r i a l
oxygen partial pressure; MABP, mean arterial blood pressure; T, rectal temperature.
cellular, cytokine and transcription factor levels in ischemic
stroke.
2.Methods
2.1. Animals. All protocols were approved by the Animal
Care Committee (Institute of Science and Technology,
Jiangsu Province, China). All procedures were performed
under the guideline published in the NIH guide for the
Care and Use of Laboratory Animals (National Institutes
of Health Publication no. 85-23, revised 1985). Adult
male Sprague-Dawley rats (220–250g) were provided by
Model Animal Research Centre of Jinling Hospital (Nanjing,
Jiangsu, China). The rats were housed under controlled
environmental conditions with ambient temperature of
25◦C,relative humidityof65%,and 12/12-hlight-dark cycle.
Food and water were provided ad libitum.A l le ﬀorts were
made to minimize the number of animals used and their
suﬀerings.
2.2. Experimental Groups. The rats used in the study were
randomized into control (n = 18), only vehicle was given,
BDNFgroup(n = 18),BDNFwasgiven,andantibody group
(n = 18), BDNF antibody was induced. The procedure was
shown in Table 1.
2.3. Administration of Drugs. Rats were anesthetized with
pentobarbital sodium (40mg/kg i.p., Sigma-Aldrich, USA)
and placed in a stereotaxic frame. Stereotaxic injections were
made by Hamilton syringe using the following coordinates:
0.5mm rostral to bregma, 3.5mm lateral to midline, and
5.5mm ventral to the skull surface. Rats in control group
were given 10μL phosphate buﬀered saline (PBS, pH 7.4);
rats in antibody group were given 5μg BDNF antibody
(PeproTech, USA) diluted in 10μL PBS (pH 7.4); rats in
BDNF group were given 10μg BDNF (PeproTech, USA)
diluted in 10μL PBS (pH 7.4). At the end of injection, the
needle was left in place for 5 minutes before being slowly
withdrawn.
2.4. Transient Middle Cerebral Artery Occlusion (MCAO)
and Reperfusion. The MCAO procedure has been described
before [15]. In brief, rats were anesthetized with pentobarbi-
tal sodium (40mg/kg i.p.). Carotid artery was exposed and
a 4-0 silicone-coated nylon ﬁlament was gently advanced
from external carotid artery into the lumen of internal
carotid artery until the rounded tip blocked the origin
of the middle cerebral artery. A laser Doppler ﬂow meter
(LDF; Perimed PF5000, Stockholm, Sweden) was used to
conﬁrm the decrease of the middle cerebral artery blood
ﬂow immediately after the occlusion to about 20% of
the basic cerebral blood ﬂow. After 2 hours, rats were
brieﬂy reanesthetized and the ﬁlament withdrawn. Rectal
temperature was maintained at 37◦Cu s i n gar e c t a lp r o b e
andheatingpadduringthesurgery.Physiologicalparameters
were monitored pre- and during ischemia (Table 2).
2.5. Tissue Processing. Rats were sacriﬁced at 6h and 24h
of reperfusion. Rats were deeply anesthetized. For real-
timequantitativePCR,enzyme-linkedimmunosorbentassay
and electrophoretic mobility shift assay, rats were perfused
transcardially with 0.1M PBS (pH 7.4) only, and brains
were removed rapidly and stored in the liquid nitrogen
until used; for immunoﬂuorescence, rats were perfused
transcardially with 0.1M PBS (pH 7.4) followed by a ﬁxative
solution containing 4% paraformaldehyde in PBS (pH 7.4).
Brains were removed and ﬁxed in the same ﬁxative solution
for an additional 6–12h in 4◦C. Prior to cytosectioning,Mediators of Inﬂammation 3
tissues were cryoprotected using 20% sucrose in PB for 24h
followed 30% sucrose in PB for 48h.
2.6. 2,3,5-Triphenyltetrazolium Chloride (TTC) and Terminal
Deoxynucleotidyl Transferase-Mediated dUTP End-Labeling
(TUNEL) Assay. For TTC staining, ﬁve coronal sections
were made from the bremega to the cerebellum and stained
with 2% TTC (Sigma-Aldrich, USA) at 37◦Cf o r3 0m i n u t e s .
The infarct area of each section was measured in a blinded
manner using Image J (NIH, USA). The infarct volume was
then calculated by Swanson’s method [16]. To determine
apoptosis-likecelldeath,TUNELstaining (InSituCellDeath
D e t e c t i o nK i t ,P O D ;R o c h e ,U S A )w a sp e r f o r m e d2 4ha f t e r
reperfusion (n = 6). The brain slices were mounted onto
slides, ﬁxed 20 minutes with 4% paraformaldehyde in PBS
(pH 7.4), and pretreated with 3% H2O2 in methanol and
0.1% Triton X-100. The TdT enzyme and nucleotide mix
were then added at proportions speciﬁed by the kit for
60 minutes at 37◦C The slides were washed 3 times with
PBS (pH 7.4). 50μL horse-radish peroxidase (POD) was
added and slides were incubated in a humidiﬁed chamber
for 30 minutes at 37◦C .A f t e rw a s h e d3t i m e sw i t hP B S( p H
7.4), 75μL diaminobenzidine (DAB) was added. Slides were
incubated for 10 minutes at room temperature. The slides
were mountedunderglass coverslipandanalyzed under light
microscope.
2.7. Behavioral Testing. Following recovery from anesthe-
sia, behavioral neurologic deﬁcits were assessed 24h after
MCAO. The battery consisted of four tests to systematically
evaluatemotor,sensory,andvestibulomotordeﬁcits.Thefol-
lowing behavioral tests were performed. Postural reﬂex and
hemiparesis test as described before [17]: (0) no observable
neurologic deﬁcits, (1) left forepaw ﬂexion, (2) decreased
resistance to lateral push and forepaw ﬂexion without
circling, (3) decreased resistance to lateral push and forepaw
ﬂexion with circling, and (4) cannot walk spontaneously.
Forepaw placing test was done as described previously
[18]. For each test, limb placing scores were as follows:
(0) immediate and complete placing, (1) delayed and/or
incomplete (>2s), and (2) no placing.
Modiﬁed beam balance test was done as described [19]:
The scale was as follows: (1) steady posture with paws on
top of the beam, (2) paws on side of the beam or wavering,
(3) one or two lim(s) Slip oﬀ, (4) three limbs slip oﬀ,( 5 )
attempts with paws on the beam, but falls, and (6) drapes
over the beam, then falls or falls with no attempt.
Adhesive tape test was done as before [20]: The scale was
evaluated as: (1) <10 seconds; (2) 10–19 seconds; (3) 20–29
seconds; (4) 30–39 seconds; (5) 40–49 seconds; (6) 50–59
seconds; (7) ≥60 seconds.
2.8. Immunoﬂuorescence. All sections (7μm) were simulta-
neously run to ensure identical staining conditions. After
rinsing in PBS (pH 7.4), sections were incubated at 37◦C
for 2h with the primary antibodies in PBS (OX-42 in pH
7.4, ED1 in pH 7.2) used at the following dilutions: OX-42
(1/200), ED-1 (1/200) (AbD Serotec, UK). After 4 washes,
antibody visualization was achieved by the incubation at
37◦C for 30 minutes with Alexa Fluor 488-conjugated don-
key antimouse (1/200) (Invitrogen, USA). Negative controls
were prepared by omitting the primary antibodies. Sections
were thencoverslippedwith a ﬂuorescentmounting medium
(Sigma-Aldrich, USA). Sections were stored at 4◦Cu n t i l
viewing. Sections were viewed under a Leica SP5 confocal
microscope (Leica, France).
2.9. Enzyme-Linked Immunosorbent Assay (ELISA). At 6h
and 24h of reperfusion, 6 rats of each group were sacriﬁced
and brain homogenates were obtained from the ischemic
hemisphere. The concentrations of BDNF, IL-10 and TNF-
α in brain homogenates were measured using speciﬁc ELISA
kits according to the manufacturers’ instructions (R&D
system, USA).
2.10. Real-Time Quantitative PCR. Total RNA was isolated
from frozen brain tissues using the TRIzol reagent (Invitro-
gen,USA)accordingtothemanufacturer’s recommendation,
and subjected to DNase (Promega, USA) treatment. Reverse
transcription (RT) reaction was carried out using the First-
strand cDNA synthesis kit (Takara, Japan) according to the
manufacturer’s instructions. Obtained cDNAwere ampliﬁed
using the following primers: for TNF-α,5  -GCATGA-
TCCGAGATGTGGAA-3  and 5 -AGACACCGCCTGGAG-
TTCTG-3 , for IL-10, 5 -CCTTACTGCAGGACTTTAAGG-
GTTA-3  and 5 -CTGGGCCATGGTTCTCT-3 ,a n df o rβ-
actin, 5 -GACAGGATGCAGAAGGAGATTACT-3  and 5 -
TGATCCACATCTGCTGGAAGGT-3 .T h ea m p l i ﬁ c a t i o n
and data acquisition were run on a real time PCR system
(Bio-Rad, USA) using SYBR green PCR Master Mix (Takara,
Japan). The conditions were predenaturation at 95◦Cf o r1 0
minutes, followed by 40 cycles at 95◦C for 15 seconds and
55◦C for 1 minute. All samples were analysed in triplicates
in three independent experiments. Reactions without cDNA
were used as no template control and no RT controls were
also set up to rule out genomic DNA contamination. Gene
expression levels were calculated using the 2−ddCt method
[21].
2.11. Electrophoretic Mobility Shift Assay (EMSA). Nuclear
extracts were prepared by hypotonic lysis followed by
high salt extraction. EMSA was performed using a kit
(Gel Shift Assay System, Promega, USA) to assay NF-κB
DNA-binding activities. The NF-κB oligonucleotide probe,
5 -AGTTGAGGGGACTTTCCCAGGC-3 , was end-labeled
with [γ-32P]. Protein-DNA binding assays were performed
with 50μg of nuclear protein. The binding medium con-
tained 4% glycerol, 1% NP40, 1mMMgCl2,5 0 m M N a C l ,
0.5mM EDTA, 0.5mM DTT, and 10mM Tris/HCl (pH
7.5). In each reaction, 20000cpm of a radiolabeled probe
was included. Samples were incubated at room tempera-
ture for 15 minutes, and nuclear protein with 32P-labeled
oligonucleotide complex was separated from free 32P-labeled
oligonucleotideby electrophoresisthrough a4% native poly-
acrylamide gel in 0.5×TBE. After separation was achieved,4 Mediators of Inﬂammation
Table 3: BDNF-reducing neurologic deﬁcits.
Postural reﬂex and hemiparesis test Forepaw placing test Modiﬁed beam balance test Adhesive tape test
Remove Contact
Control 2.8 ±0.41 5.2 ±0.75 4.2 ±0.75 5.7 ± 0.82 4.5 ±1.05
BDNF 1.5 ±0.55
∗ 3.8 ±0.98
∗ 2.2 ±0.98
∗ 4.3 ± 1.21 4.8 ±0.75
Antibody 3.2 ±0.75 5.5 ±1.05 4.2 ±0.98 5.8 ± 1.33 4.5 ±0.55
∗P<. 05 versus control group.
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Figure 1: The concentration of BDNF in brain one hour before
ischemia, 5μgo fB D N Fa n t i b o d yi n1 0μLP B Sw a si n j e c t e dt ot h e
brain of rats. 10μgB D N Fi n1 0μL PBS was given immediately after
ischemia. At 6h and 24h of reperfusion, rats were sacriﬁced and
brains were removed. The concentration of BDNF was measured
after reperfusion using ELISA kits. The level of BDNF was
s i g n i ﬁ c a n t l yi n c r e a s e di nB D N Fg r o u pb o t h6 ha n d2 4 ha f t e r
reperfusion. Bars represent mean±SD (n = 6). ∗P<. 05 versus
control group, #P <. 05 versus BDNF group.
the gel was dried (80◦C, 30 minutes) and exposed to X-ray
ﬁlm (Fuji Hyperﬁlm) at −80◦C with an intensifying screed.
2.12. Cell Counting. Images from brain sections with
immunoﬂuorescence were captured and analyzed by using
Image-Pro Plus 6.0. Cells were counted in the ischemic
cortex. 5 slides, 2mm interval from bregma, were used for
counting in each rat. 6 random areas of each slide were
involved and the average number of OX-42 or ED1-positive
cells/mm2 was calculated.
2.13. Statistical Analysis. The data were presented as
mean±SD. Diﬀerences between groups were compared
using analysis of variance (ANOVA) followed by post hoc t-
test with SPSS13.0 software (USA). P<. 05 was considered
to be statistically signiﬁcant.
3.Results
3.1.BDNFLevelwasIncreased inBrain. Toassess theconcen-
trationofBDNFinbraintissues,thebrainhomogenateswere
obtained6hand24hafterreperfusionandtheconcentration
of BDNF was measured using ELISA kits. BDNF level was
signiﬁcantly increased by 19.7 fold in BDNF group while
administration of BDNF antibody did not inﬂuence BDNF
level in brain (1.00±0.05 versus 0.98±0.13ng/g, n = 6, P>
.05, Figure 1). The concentration of BDNF was decreased at
24h of reperfusion than that at 6h of reperfusion; however,
it was signiﬁcantly increased compared with control group
(11.36 ± 0.91 versus 1.42 ± 0.08ng/g, n = 6, P<. 05,
Figure 1). There was no signiﬁcant diﬀerence of BDNF level
between antibody group and control group (1.38 ± 0.14
versus 1.42 ± 0.08ng/g, n = 6, P>. 05, Figure 1).
3.1.1. BDNF Protected Brain against Ischemic Insult and
Reduced Neurologic Deﬁcits. We investigated cellular injury
using TUNEL assay and measured the infarct volume using
the TTC staining while neurologic deﬁcits were tested by
four behavioral tests 24h after reperfusion. The number
of TUNEL-positive cells in BDNF group was signiﬁcantly
decreased than that in control group (n = 6, 23.05 ± 1.86
versus 54.26 ± 3.05%, P<. 05, Figures 2(d), 2(e), 2(h))
while BDNF antibody did not increased the TUNEL positive
cells (n = 6, 55.06 ± 2.57 versus 54.26 ± 3.05%, P>
.05, Figures 2(d), 2(f), 2(h)). However, the infarct volume
measurements were found to be similar in the three groups
with no statistical diﬀerences. ExogenousBDNFsigniﬁcantly
improved motor-sensory function (1.5 ± 0.55 versus 2.8 ±
0.41, P<. 05, Table 3), sensorimotor function (3.8 ± 0.98
versus 5.2 ± 0.75, P<. 05, Table 3), vestibulomotor function
(2.2 ± 0.98 versus 4.2 ± 0.75, P<. 05, Table 3)c o m p a r e d
with control group while BDNF antibody did not change
the functions above. There was no signiﬁcant diﬀerence of
somatosensory function in the three groups (Table 3).
3.2. BDNF Increased the Number of Activated Microglia
in Brain. Activated microglia could be marked by OX-42
and detected by immunoﬂuorescence. BDNF increased the
number of activated microglia compared to control group
(394.7 ± 31.5 versus 272.0 ± 22.6/mm2, n = 6, P<. 05,
Figure 2) as early as 6h after reperfusion. On the other side,
when endogenous BDNF’s activity was suppressed by BDNF
antibody, thenumber ofactivated microglia was signiﬁcantly
decreased (90.7 ± 19.4 versus 272.0 ± 22.6/mm2, n = 6,Mediators of Inﬂammation 5
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Figure 2: BDNF alleviated cellular injury of ischemic insult brain tissue sections obtained from injured cerebral hemispheres were stained
with triphenyltetrazolium chloride (TTC) and TUNEL assay 24h after reperfusion. (a) Infarct volume without any treatment. (b) Infarct
volume with exogenous BDNF. (c) Infarct volume with exogenous BDNF antibody. (d) TUNEL assay in control group. (e) TUNEL assay
in BDNF group. (f) TUNEL assay in antibody group. (g) No signiﬁcant diﬀerence of infarct volume in the three groups. (h) Summary of
TUNEL-positive cells 24h after ischemia. Scar bar: 100μm. Bars represent mean±SD (n = 6); ∗P<. 05 versus control group.
P<. 05, Figure 2). At 24h of reperfusion, more microglia
wereactivatedinBDNFgroupthanincontrolgroup(408.0±
22.1 versus 277.3 ± 21.9/mm2, n = 6, P<. 05, Figure 2).
However, there was no signiﬁcant diﬀerence of the number
of activated microglia between antibody group and control
group (266.7±24.1versus277.3±21.9/mm2, n = 6, P>. 05,
Figure 2).
3.3. BDNF Increased the Number of Phagocytotic Microglia
in Brain. ED1 is a marker of phagocytotic microglia which
could engulf damaged cells and other inﬂammatory cells.
The number of phagocytotic microglia in brain was signif-
icantly increased in BDNF group than in control group 6h
after reperfusion (378.7±13.1versus 237.3±18.7/mm2, n =
6, P<. 05, Figure 3). BDNF antibody, which could blocked
the eﬀect of BDNF, decreased the number of ED1 positive
microglia (82.7 ± 12.0 versus 237.3 ± 18.7/mm2, n = 6, P<
.05, Figure 3) 6h after reperfusion. At 24h of reperfusion,
exogenous BDNF increased the number of phagocytotic
microglia (325.3 ± 19.4 versus 138.7 ± 16.5/mm2, n = 6,
P<. 05, Figure 3). However, the number of ED1 positive
microglia showed nosigniﬁcant diﬀerenceinantibody group
compared with control group (154.2 ± 26.5 versus 138.7 ±
16.5/mm2, n = 6, P>. 05, Figure 3).
3.4. BDNF Promoted Anti-Inﬂammatory Cytokine Expression.
IL10 is a well-known anti-inﬂammatory cytokine. IL-10 and
its mRNA expression were tested by ELISA kits and real time
qPCR, respectively. When BDNF antibody blocked activity
of endogenous BDNFin brain, IL10 was markedly decreased
compared to control group (10.85 ± 0.48 versus 14.28 ±
0.82ng/g, n = 6, P<. 05, Figure 4(a)). Application of BDNF
antibodyalsopreventedupregulationofIL10mRNA6hafter
reperfusion (0.50 ± 0.02 versus 1.01 ± 0.09, n = 6, P<. 05,
Figure 5(a)). However, there was no signiﬁcant diﬀerence
of IL10 and its mRNA expression between BDNF group
and control group 6h after reperfusion. Exogenous BDNF
markedly increased local IL10 level in brain tissues 24h after
reperfusion (19.80 ± 0.83 versus 13.31 ± 0.36ng/g, n = 6,
P<. 05,Figure 4(a))andincreasedmRNAexpressionby1.93
foldcomparedwithcontrolgroup .H owever ,BDNFantibody
did not inﬂuence the level of IL10 and its mRNA 24h after
reperfusion.
3.5. BDNF Inhibited Proinﬂammatory Cytokine Expression.
TNF-αisaproinﬂammatory cytokine.To determinewhether
BDNF inhibited local TNF-α in ischemic brain tissues, we
used ELISA kits and real-time qRCR to measure TNF-α and
its mRNA expression, respectively. Giving exogenous BDNF
inhibited TNF-α (11.23 ± 0.46 versus 14.33 ± 0.63ng/g, n =
6, P<. 05, Figure 4(b)) while suppression of endogenous
BDNF by BDNF antibody upregulated TNF-α (19.76 ± 0.81
versus 14.33±0.63ng/g, n = 6,P<. 05,Figure 4(b))6hafter
reperfusion. Exogenous BDNF also signiﬁcantly decreased
TNF-α (9.59 ± 0.44 versus 12.85 ± 0.67ng/g, n = 6, P<. 05,
Figure 4(b)) at 24h of reperfusion. On mRNA level, BDNF
inhibited mRNA expression of brain TNF-α after stroke at
both 6h (0.39 ± 0.01 versus 1.00 ± 0.06, n = 6, P<. 05,6 Mediators of Inﬂammation
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Figure 3: BDNF increasing the number of activated microglia after stroke Activated microglia in brain was marked by OX-42 and detected
by confocal microscope following immunoﬂuorescence. (a–c) 6h after reperfusion and (e–g) 24h after reperfusion; (a, e) control group,
(b, f) BDNF group and (c, g) antibody group. (h) The number of phagocytotic microglia in BDNF group was signiﬁcantly increased than
control group 6h and24h after reperfusion. BDNF antibody signiﬁcantlydecreased the number of activated microglia 6h after reperfusion.
Bars represent mean±SD (n = 6). ∗P<. 05 versus control group, #P <. 05 versus BDNF group. Scale bars: 25μm.
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Figure 4: BDNF upregulating the number of phagocytotic microglia after stroke ED1 is well known as a marker of phagocytotic microglia.
(a–c) 6h after reperfusion and (d–f) 24h after reperfusion; (a, d) control group, (b, e) BDNF group and (c, f) antibody group. BDNF
signiﬁcantlyincreased the number of phagocytotic microglia in brain 6h and 24h after reperfusion. The number of activated microglia was
decreased in BDNF antibody group at 6h of reperfusion. Bars represent mean±SD (n = 6). ∗P<. 05 versus control group, #P <. 05 versus
BDNF group. Scale bars: 25μm.
Figure 5(b))a n d2 4h( 0 .77 ± 0.04 versus 0.91 ± 0.06, n = 6,
P<. 05, Figure 5(b)) of reperfusion. The mRNA of TNF-
α was increased by 2.28 fold in antibody group 6h after
reperfusion. However, BDNF antibody did not inﬂuence the
TNF-α and its mRNA 24h after reperfusion.
3.6. BDNF Increased DNA-Binding Activity of NF-κBa f t e r
Stroke. The DNA-bindingactivity of NF-κB was activated by
many stresses such as ischemia, the activity was measured
using EMSA and expressed as arbitrary densitometric units
(AU). Exogenous BDNF increased DNA binding activity of
NF-κB by 10.7% compared with control group 6h after
reperfusion, and when endogenous BDNF was suppressed
by BDNF antibody, the activity was signiﬁcantly decreased
(35.92 ± 0.99 versus 39.97 ± 0.70, n = 6, P<. 05, Figure 6).
At 24h of reperfusion, exogenous BDNF could signiﬁcantly
increase DNA bind activity compared with control group
(45.38 ± 0.86 versus 42.46 ± 0.27, n = 6, P<. 05, Figure 6).Mediators of Inﬂammation 7
0
7
14
21
I
L
-
1
0
(
n
g
/
g
)
∗
∗#
#
6h 24h
Control
BDNF
Antibody
(a)
0
7
14
21
∗
∗
∗#
#
6h 24h
Control
BDNF
Antibody
T
N
F
-
α
(
n
g
/
g
)
(b)
Figure 5: BDNF modulating local cytokine in brain after stroke Interleukin10 (IL10) and tumor necrosis factor α (TNF-α) in rat brain
after strokewere measured using ELISA kits. (a) Exogenous BDNF upregulated IL-10 24h after reperfusion while BDNF antibody decreased
IL-10 6h after reperfusion. (b) Exogenous BDNF decreased TNF-α at 6h and 24h of reperfusion than control group and BDNF antibody
overwhelmed the eﬀect. Bars represent mean±SD (n = 6). ∗P<. 05 versus control group, #P<. 05 versus BDNF group.
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Figure 6: Eﬀect of BDNF on mRNA expression of cytokine brain homogenates were obtained from ischemic cortexes 6h and 24h after
reperfusion. The expressions of mRNA of interleukin10 (IL10) and tumor necrosis factor α (TNF-α) in rat brain after stroke were measured
byreal-timequantitativepolymerasechainreaction(PCR).(a)LevelsofIL10mRNA.ApplicationofBDNF antibody prevented upregulation
ofIL10 mRNA 6h after reperfusion. At 24h ofreperfusion, BDNF increased level of mRNA ofIL10 by 1.93fold. (b) Levels if TNF-α mRNA.
Exogenous BDNF signiﬁcantly decreased mRNA of TNF-α 6h and 24h after reperfusion. Inhibition of endogenous BDNF signiﬁcantly
increased the expression of TNF-α 6h after reperfusion. Bars represent mean±SD (n = 6). ∗P<. 05 versus control group, #P <. 05 versus
BDNF group.8 Mediators of Inﬂammation
However, there is no signiﬁcant diﬀerence between antibody
group and control group (41.43 ± 1.18 versus 42.46 ± 0.27,
n = 6, P>. 05, Figure 6).
4.Discussion
Our data suggested that BDNF could alleviate cellular injury
of ischemic insult, reduce the neurologic deﬁcits and mod-
ulate local inﬂammation on cellular, cytokine and nuclear
factor levels in brain after stroke. Exogenous BDNF could
increasethenumberofactivatedand phagocytoticmicroglia,
upregulate IL-10, downregulate TNF-α and increase the
DNA-binding activity of NF-κB while BDNF antibody
blocked these eﬀects of BDNF in ischemic brain tissues.
Firstly, we showed that introducing BDNF directly to
brain increased the concentration of BDNF. We also found
thatBDNFantibodymaynotchangetheexpressionofBDNF
in brain tissues after stroke. Our data conﬁrm previous
reports that injection of BDNF directly to brain could raise
concentration of BDNF.
Secondly, exogenous BDNF could protect brain from
ischemic injury and reduce the neurologic deﬁcits. We found
exogenous BDNF signiﬁcantly decreased the number of
TUNEL-positive cells. We also found that BDNF improved
the motor-sensory function, sensorimotor function, and
vestibulomotor function. Our results were consistent with
previous reports [22, 23]. However, BDNF may not reduce
the infarct volume which was diﬀerent from some previous
researches [3, 24]. Sch¨ abitz et al. [22] also found that BDNF
may not change the infarct volume.
Thirdly, we provided evidences that BDNF modulated
local inﬂammation in ischemic brain tissues on cellular,
cytokine and transcript levels. On cellular level of local
inﬂammation, we found that exogenous BDNF could
increase the number of both activated and phagocytotic
microglia as early as 6h after reperfusion and lasted at
least for 24h. When the activity of endogenous BDNF
was blocked by BDNF antibody, the number of activated
and phagocytotic microglia was decreased. Previous reports
showed that BDNF could promote microglial proliferation
and phagocytic activity in vitro and in vivo and inhibit
microglial apoptosis [11, 12]. These results were consistent
with our data. The mechanism BDNF activates microglia
might be that BDNF could sustain elevation of intracellular
Ca2+ of microglia [25, 26]. It is well accepted that activated
microglia protects the brain against ischemic and excitotoxic
injury [27]. Once microglia activated, it could excrete
neurotrophins such as BDNF. BDNF could protect neurons
against ischemia. More BDNF could activate more microglia
and it is an autoloop. Phagocytotic microglia could engulf
damaged cells and other inﬂammatory cells which may
initiate more damage to brain in ischemic stroke. These
may partly explain the protection of BDNF against ischemic
insult.
Oncytokinelevelofbrainlocalinﬂammation inischemic
stroke, we found that BDNF could decrease brain TNF-
α in ischemic stroke. Exogenous administration of BDNF
decreased brain TNF-α and inhibited the mRNA expression
of TNF-α. When the activity of BDNF was blocked by its
antibody, the protein level and mRNA expression of local
TNF-αin brainwere decreased. These resultswere consistent
with previous research, which shows that exogenous BDNF
inhibits the expression of TNF-α in mouse brain of model
of multiple sclerosis [13]. TNF-α, an important proinﬂam-
matory cytokine, plays a vital role in the pathophysiology
of ischemia stroke [6]. Exogenous administration of TNF-α
exacerbates ischemic brain injury while inhibition of TNF-
α could reduce brain damage [8, 28]. BDNF could provide
protection of brain in ischemic stroke via decreasing local
TNF-α.
BDNF not only decreased local proinﬂammatory
cytokine, it also increased local anti-inﬂammatory cytokine.
IL10 is an important anti-inﬂammatory cytokine. Our data
showed BDNF increased the level of IL10 and upregulated
the mRNA expression of IL10 at 24h of reperfusion.
Once activity of endogenous BDNF was blocked by
BDNF antibody, local IL-10 and its mRNA in brain
were increased. These results were consistent with other
studies [13]. Previous publications showed that exogenous
pre/postischemic administration of IL10 can provide
neuroprotection following MCAO [9, 29]. Over-expression
of IL10 in vivo markedly protected cortical tissue against
cerebral ischemia using th eI L 1 0t r a n s g e n em i c e[ 30]. Our
datasuggestedthat BDNFmight protect brainfrom ischemia
through upregulating local IL10 in brain.
On the transcription level of local inﬂammation in
b r a i ni ni s c h e m i cs t r o k eo fr a t s ,w ef o u n dt h a te x o g e n o u s
BDNFincreased theDNA-bindingactivity ofNF-κB.Wealso
provided evidence that the DNA-binding activity of NF-κB
wasinhibitedwhentheeﬀectofBDNFwassuppressed.These
resultsindicatedthatBDNFcouldmodulateNF-κB’sactivity.
The way BDNF activates NF-κBi nd i ﬀerent cells is through
the TrkB-PI3-kinase-Akt pathway [31]. Inhibition of TrkB,
the receptor of BDNF in the cell, decreases the activation
of NF-κB[ 32]. The activation of NF-κB induced by BDNF
protects cells from a variety of damages, including the serum
starvation, glutamate toxicity and ischemia [14]. Once the
activity of NF-κBw a si n h i b i t e db yd i ﬀerent inhibitors, the
protectionsofBDNFagainst diﬀerentdamageswere lessened
[31]. Our data suggested that NF-κB played an important
role in neuron protection of BDNF.
In our study, eﬀect of BDNF on local inﬂammation in
brain showed no signiﬁcant diﬀerence between antibody
group and control group 24h after reperfusion. This may
because that BDNF antibody only blocked the activity of
BDNFand may not suppressed the expression oflocal BDNF
in brain after stroke. Our data showed that BDNF antibody
did not change BDNF level (Figure 1). 24h after reperfusion
(25h after BDNF antibody was given), the expression of new
BDNF may replace the antibody-conjuncted BDNF, so the
eﬀect of BDNF antibody might be removed.
5.Conclusions
In summary, our data suggested that BDNF may alleviate
cellular injury of ischemic insult, reduce the neurologicMediators of Inﬂammation 9
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Figure 7: BDNF enhancing DNA-binding activity of NF-κB The DNA-binding activity of NF-κBi ni s c h e m i cc o r t e xi nt h r e eg r o u p s
was measured using Electrophoretic mobility shift assay (EMSA) 6h and 24h after reperfusion. Levels of NFκB DNA binding activity
were expressed as arbitrary densitometric units (AU.) using Image J. Exogenous BDNF increased the activity of NF-κB6 ha n d2 4 h
after reperfusion. Inhibition of endogenous BDNF by its antibody signiﬁcantly decreased the activity 6h after reperfusion. Bars represent
mean±SD (n = 6). ∗P<. 05 versus control group, #P <. 05 versus BDNF group.
deﬁcits and modulate local inﬂammation on cellular level,
cytokine level, and transcription factor level in ischemic
stroke.
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